AQP4 and myeloid sarcoma: As a secondary aim, we sought to establish cutoff values by comparing the AQP4-IgG titers measured using AQP4-CLEIA from patients with AQP4-IgG-positive NMOSD, MS, and MOGAD and from healthy individuals, and we compared the clinical performance of this assay with that of a microscopic live CBA.